ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

Please complete the ABSTRACT TEMPLATE online, for Biomed 2025 Company Presentations
All items marked with an * are mandatory to complete
The maximum number of words for this abstract is 400
Please be sure to complete the following:

Company name PhaseV * Website https://phasevtrials.com/ *

CEO name Raviv Pryluk

CATEGORY: Biotech

Select up to two SESSIONS per abstract from the list below *
(Delete sessions you are not selecting)

- AI Meets Pharma: Building a Sustainable Value for Biotech AI innovation in Drug Development

Raviv Pryluk, PhD
CEO, Co-Founder, PhaseV
raviv@phasevtrials.com

Title: AI-Powered Trials: Driving Sustainable Innovation and Impact in Biotech Drug Development

As biotech companies seek sustainable innovation in an increasingly complex drug development landscape, artificial intelligence is emerging as a critical force multiplier. This session explores how AI-driven platforms like PhaseV's are transforming clinical trials. By combining causal inference, adaptive trial design, and high-quality data, we'll demonstrate how AI can deliver measurable improvements in trial precision, reduce costs, time to market, and increase the probability of success.
Through real use cases, attendees will gain insight into how AI enables earlier decision-making, better patient targeting, and smarter resource allocation. We'll also look ahead to how vertically integrated AI solutions are shaping a more sustainable, data-native future for biotech innovation.

Dr. Raviv Pryluk is co-founder and CEO of PhaseV, a pioneer in causal machine learning (ML) for clinical trial analysis and optimization. Prior to his tenure at PhaseV, Dr. Pryluk held integral roles in operations and data analytics at Immunai, a biotechnology company specializing in the mapping and reprogramming of immunology. Before that, Dr. Pryluk was a technological leader in the advanced technological defense industry for over a decade. He holds a BSc and MSc in aerospace, aeronautical, and astronautical engineering from Technion (Cum Laude) and a Ph.D. in neurobiology and neurosciences from the Weizmann Institute of Science (Summa cum laude).